Thyrocare Technologies Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹223.95 crore for Q4 FY26, marking a 20% year-on-year growth, primarily driven by a 21% increase in the Pathology segment. Franchise revenue in the Pathology business grew by 21% year-on-year, while partnership revenue recorded a 23% year-on-year growth. The company processed 59.0 million tests in Q4 FY26, a 29% year-on-year increase, reinforcing its position as India's largest diagnostic test volume processor. Consolidated EBITDA grew by 31% year-on-year to ₹75.09 crore, and Profit After Tax (PAT) surged by 128% year-on-year to ₹48.70 crore. The company maintained Six Sigma quality standards, reducing complaints per million tests to 3.1 (down 34% YoY) with an Average Turnaround Time (ATAT) of 3.43 hours. Thyrocare also expanded its test portfolio with advanced allergy testing and ventured into genomics with a new lab and the launch of Non-invasive Prenatal Testing (NIPT). For the full financial year 2026 (FY26), consolidated revenue grew 21% year-on-year to ₹829.04 crore. Pathology business franchise revenue increased by 18% YoY, while partnership revenue grew by 32% YoY. Test volumes for the year reached 209.6 million, a 23% YoY growth. Consolidated EBITDA rose 38% YoY to ₹262.04 crore, and PAT grew 81% YoY to ₹162.85 crore. Rahul Guha, MD & CEO of Thyrocare Technologies Ltd., stated, “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.”
